Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom Regulation topic
No spam. Unsubscribe anytime.
Heated testimony on kratom: families push for bans while industry, vets and researchers urge regulation, not prohibition
Summary
The committee heard divergent testimony on multiple kratom bills: family members urged bans after alleged harms, while industry representatives, recovery advocates, veteran groups and researchers supported consumer-protection regulation or continued access for therapeutic use.
The Joint Committee on the Judiciary heard sharply contrasting testimony on proposed kratom legislation, including bills that would ban sales and others that would create a consumer-protection regulatory framework.
Family members and some court observers urged the committee to classify kratom as a controlled substance or support local bans. “Kratom is currently unregulated and readily available in various forms,” said one witness who described a family member’s medical emergency and said the judge at a civil petition called kratom “gas-station heroin.” The family witness asked the legislature to act statewide so municipal patchwork bans are not the sole response.
Opposing a full ban, industry advocates, vetted instructors, researchers and veteran-recovery programs urged targeted regulation. Mac Haddow of the American Kratom Association said the scientific record did not support wholesale scheduling and urged adoption of a Kratom Consumer Protection Act (proposal mentioned: H 2454) to require independent lab testing, bans on synthetic adulterants, good manufacturing practices and clear labeling.
Researchers and pharmacists cautioned against conflating adulterated, synthetic compounds found in some retail products with whole-leaf kratom. Charles White, a pharmacist and university professor, told the committee that some recent “gas-station heroin” products are experimentally synthesized compounds and not the natural leaf; he recommended regulation to require independent certificates of analysis, age limits and lab testing rather than an outright ban.
Veterans’ and recovery advocates said kratom and newer 7‑hydroxy derivatives have been used as tools to reduce opioid use and save lives. John Shinholster of American Veterans for Kratom Safety described small-scale programs that supported detox and recovery. Other witnesses said preliminary data and market patterns suggested opioid-overdose reductions coincident with the introduction of certain products and argued prohibition would drive consumers to the black market and illicit opioids.
Several witnesses and researchers urged the committee to distinguish between whole-leaf kratom (used traditionally and sold as tea, powders or capsules) and concentrated or semi-synthetic derivatives that carry higher risk. Proposals discussed included H 16-80 (a ban), H 16-31 (sale restrictions), and H 24-54/H 02-1954 (a consumer-protection model referenced by supporters).
Committee members asked for scientific evidence, data on overdose attribution and clarity on how synthetic adulterants are entering the retail market. The hearing record contains multiple written submissions and indicated several towns have enacted local bans; proponents of regulatory models offered draft statutory language used in other states as templates.
